reports
Texas Pacific Land Corp: 1 director
A director at Texas Pacific Land Corp bought 10 shares at 1,399.380USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 183,885 shares of the Company’s common stock to seven new employees (the “Inducement G...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stoc...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stock Dividends EFFINGHAM, Ill., May 06, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that its Board of Directors declared a quarterly cash dividend of $0.31 per share of its common stock. The dividend is payable on May 23, 2025 to all shareholders of record as of the close of business on May 16, 2025. The Board of Directors also declared a cash dividend of $0.4844 per depository share on its 7.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The dividend will...
89bio to Participate in Upcoming Investor Conferences
89bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May: BofA Securities 2025 Health Care ConferenceFormat: Fireside ChatDate: Wednesday, May 14, 2025Time: 1:40 PM ET 2025 RBC Capital Markets Gl...
89bio Reports First Quarter 2025 Financial Results and Corporate Updat...
89bio Reports First Quarter 2025 Financial Results and Corporate Updates – Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; completed...
Midland States Bancorp, Inc. Announces Preliminary 2025 First Quarter ...
Midland States Bancorp, Inc. Announces Preliminary 2025 First Quarter Results EFFINGHAM, Ill., April 30, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) (the “Company”) reported preliminary results for the first quarter of 2025. As previously disclosed, the Company is completing its evaluation, subject to review by its independent registered public accounting firm, of the accounting and financial reporting of third-party lending and servicing arrangements, including the collection and analysis of third-party documentation, not material to tangible equity. This process...
Midland States Bancorp, Inc. receives expected notification of deficie...
Midland States Bancorp, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of Annual Report on Form 10-K EFFINGHAM, Ill., April 09, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) (the “Company”) today announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on April 3, 2025 (the “Notice”). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timel...
89bio to Participate in the Leerink Partners Global Healthcare Confere...
89bio to Participate in the Leerink Partners Global Healthcare Conference SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of th...
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and ...
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expec...
Midland States Bancorp Inc: 1 director
A director at Midland States Bancorp Inc bought 2,000 shares at 19.970USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company’s common stock to seven new employees (the “Inducement ...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Sto...
Midland States Bancorp, Inc. Announces Common Stock and Preferred Stock Dividends EFFINGHAM, Ill., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (NASDAQ: MSBI) announced today that its Board of Directors declared a quarterly cash dividend of $0.31 per share of its common stock. The dividend is payable on February 21, 2025 to all shareholders of record as of the close of business on February 14, 2025. The Board of Directors also declared a cash dividend of $0.4844 per depository share on its 7.75% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The d...
89bio Announces Closing of its Public Offering and Full Exercise of Un...
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it closed its previously announced underwritten public offering of 25,957,142 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional...
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Com...
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 21,671,428 shares of its common stock at a public offering price per share of $8.75 and, in lieu of common stock to a certain investor,...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common ...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common...
Midland States Bancorp, Inc. Announces 2024 Fourth Quarter Results
Midland States Bancorp, Inc. Announces 2024 Fourth Quarter Results Fourth Quarter 2024 Highlights: Net loss available to common shareholders of $54.8 million, or $2.52 per diluted shareAdjusted pre-tax, pre-provision earnings of $21.5 million, compared to $27.5 million in prior quarterSold $87.1 million LendingPoint consumer loan portfolio, recognizing net charge-offs and provision for credit losses of $17.3 millionCommitted to a plan to sell $371.7 million Greensky portfolio, recognizing net charge-offs and provision for credit losses of $33.4 millionNet charge-offs on loans of $102.7 mil...
Moody's Ratings assigns B3 rating to W&T's proposed secured notes, out...
Moody's Ratings (Moody's) assigned a B3 rating to W&T Offshore, Inc.'s (W&T) proposed new senior secured second lien notes due 2029 and changed the company's ratings outlook to stable from negative. Concurrently, we affirmed W&T's B3 Corporate Family Rating (CFR), B3-PD Probability of Default Rating...
89bio Provides Business Update and Outlook for 2025
89bio Provides Business Update and Outlook for 2025 – Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024 – SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- 89bi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.